Thanks again for your interest in the Kasey Altman hackathon to find the best next treatment for this rare cancer patient. This is our weekly update (#15), especially for those who were unable to join us in person on our last two meetings on September 9 and 16.
Kasey is in San Diego and following a healthy lifestyle while she waits for the delayed start (which has now slipped to late November from late October) of her treatment in a clinical trial of a personalized neoantigen vaccine. The delay is due to a complicated supply chain with many vendors and handoffs, overseen by UCSD. (Please see the recordings for more details.)
The prioritization event for Kasey’s contingency plans (should she have a recurrence after her personalized vaccine) with clinicians and researchers was held on Sunday, September 12. Two main insights were (1) to develop a strategy that sits on top of specific treatment recommendations, and (2) a consensus on combining an immunotherapy (such as a checkpoint inhibitor) with a treatment targeted on Kasey’s mutations (such as B7H3).
(For more on Kasey’s treatment options and priorities, please see the slide deck that was used with the prioritization panel and the meeting notes.)
Please see the recordings for more details.
In Closing: Our Request
Any thoughts on accelerating the personalized vaccine production timeline?
Best,
Kasey Altman, Delsee Altman, Lupe Montes, and Brad Power